Compare XAIR & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | BNGO |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 11.6M |
| IPO Year | 2015 | 2018 |
| Metric | XAIR | BNGO |
|---|---|---|
| Price | $1.01 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $11.00 | $6.33 |
| AVG Volume (30 Days) | ★ 335.3K | 229.9K |
| Earning Date | 05-24-2026 | 03-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,705,000.00 | ★ $12,000,735.00 |
| Revenue This Year | $126.42 | N/A |
| Revenue Next Year | $130.48 | $24.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | 26.26 |
| 52 Week Low | $0.15 | $1.06 |
| 52 Week High | $3.78 | $5.50 |
| Indicator | XAIR | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 33.38 |
| Support Level | $1.02 | $1.08 |
| Resistance Level | $1.16 | $1.23 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 43.15 | 27.59 |
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.